GLP-1 Receptor Agonists and Noncardiometabolic Outcomes

What are the associations between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and noncardiometabolic outcomes, and how credible is the available evidence?In this umbrella review of 60 meta-analyses of 1751 randomized clinical trials involving approximately 3 million participants, the most consistent associations with GLP-1 RAs were increased gastrointestinal adverse events (including nausea and vomiting). Suggested protective associations were reported for serious infections and respiratory disease, while possible associations with pancreatitis and gallbladder or biliary disease remained exploratory.This review observed signals of an association between GLP-1 RAs and lower risks of respiratory disease and serious infections; however, the credibility of the evidence was limited and require further confirmation.

Corresponding Authors: Yongze Li, PhD, Department of Endocrinology and Metabolism, The Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Hospital of China Medical University, No. 155, Nanjing Bei St, Shenyang 110001, PR China (yzli87@cmu.edu.cn); Qiqiang Guo, PhD, The College of Basic Medical Science, Health Sciences Institute, China Medical University, Shenyang, China (qqguo@cmu.edu.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.